AEZS
Aeterna Zentaris Inc.
NasdaqCM
People also watch:KERXCYCCCTICSNSSAGEN
3.44-0.07 (-1.99%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close3.51
Open3.55
Bid3.25 x 500
Ask3.58 x 300
52wk Range2.60 - 21.00
Day's Range3.39 - 3.55
Volume151,593
Avg Vol (3m)219,668
As of 4:00 PM EDT. Market closed.
  • Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016
    Capital Cube2 months ago

    Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016

    Click here to see latest analysisÆterna Zentaris, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Novartis AG Sponsored ADR, Sanofi Sponsored ADR, Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc. (SPPI-US, KERX-US, NVS-US, SNY-US, […] (Read more...) The post Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 appeared first on CapitalCube.

  • Associated Press2 months ago

    Aeterna Zentaris reports 1Q loss

    On a per-share basis, the Montreal-based company said it had a loss of 37 cents. The drug developer posted revenue of $242,000 in the period. In the final minutes of trading on Monday, the company's shares ...